Juvenile Macular Degeneration Market Report and Forecast 2025-2034
Description
The juvenile macular degeneration market was valued at USD 1.55 Billion in 2024, driven by the growing emphasis on the development of innovative treatment options across the 8 major markets. The market is expected to grow at a CAGR of 7.37% during the forecast period of 2025-2034, with the values likely to reach USD 3.16 Billion by 2034.
Juvenile Macular Degeneration Market Overview
Juvenile macular degeneration or juvenile macular dystrophy refers to a group of inherited eye disorders that occur in children and young adults. This eye condition impacts the central vision and, unlike age-related macular degeneration (AMD), impairs vision early in life. Stargardt disease is the most common form of juvenile macular dystrophy and usually results in a vision of 20/200.
The juvenile macular degeneration market is driven by the increasing prevalence of genetic eye disorders and the rising public awareness about the disease. The advancements in genetic testing and imaging technologies are also benefitting the market by augmenting the number of diagnosed cases. The growth in the volume of clinical trials investigating gene therapies and the increased focus on stem cell treatments are anticipated to bolster the market expansion in the forecast period.
Juvenile Macular Degeneration Market Growth Drivers
Increasing Cases of Juvenile Macular Degeneration to Impact Market Growth
Juvenile macular degeneration (JMD) includes inherited eye disorders such as Stargardt's disease, Best disease, and juvenile retinoschisis, which leads to central vision loss during childhood or young adulthood. In the United States, around 1 in 10,000 children are affected by Stargardt's disease. Further, it is estimated that the disease affects nearly 100,000 individuals in the United States and Europe. The growing awareness of the disease is leading to better diagnosis and management of this inherited eye condition along with prompting the affected individuals to seek treatment. Thus, the increasing cases of genetic eye disorders and the rise in the early detection of juvenile macular degeneration are projected to drive market growth in the coming years.
Juvenile Macular Degeneration Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Regulatory Support to Affect the Market Landscape Significantly
In January 2024, privately held biotech Ascidian Therapeutics announced that the US Food and Drug Administration (FDA) approved its investigational new drug (IND) application and also granted fast-track designation to its RNA-editing candidate (ACDN-01) for the treatment of Stargardt disease, allowing the company to initiate the first RNA-editing clinical trial in the United States. Such regulatory support to advance treatment for inherited eye disorders is likely to stimulate market growth in the forecast period.
Launch of Innovative Products Poised to Augment Juvenile Macular Degeneration Market Demand
In November 2023, Ocutrx Technologies, Inc., a high-tech 3D visualization company specializing in augmented reality (AR) technology, revealed its new AR/XR headset OcuLenz™, which is designed to improve visual clarity for individuals affected by advanced macular degeneration (AMD) and Stargardts (the juvenile form of AMD). The launch of such innovative products to aid people suffering from central vision loss is expected to boost the market demand.
Rising Innovations in Ophthalmology to Elevate the Juvenile Macular Degeneration Market Value
One of the significant market trends is the introduction of advanced imaging technologies, such as adaptive optics and high-resolution OCT, that facilitate detailed visualization and accurate progression of retinal disease. This also helps in evaluating the effectiveness of new therapies and is projected to encourage pharmaceutical companies to invest in the market.
Growth in Clinical Trials to Boost Juvenile Macular Degeneration Market Size
In August 2024, United States-based Ocugen, Inc., a biotech firm that develops novel gene therapies, cell therapies, and vaccines, announced the completion of dosing in the third cohort of its Phase 1/2 GARDian clinical trial that is investigating a modifier gene therapy candidate, OCU410ST (AAV-hRORA), for Stargardt disease. The surge in the number of clinical trials for inherited retinal disorders is poised to augment the market size.
Juvenile Macular Degeneration Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Type:
Market Segmentation Based on Type is Anticipated to Witness Substantial Growth Based on the type of juvenile macular degeneration, the market is segmented into dry age-related juvenile macular degeneration and wet age-related juvenile macular degeneration. Dry age-related juvenile macular degeneration is the more common form of juvenile macular degeneration, characterized by the accumulation of drusen (small yellow deposits) beneath the retina and slower progression than the wet form. On the other hand, wet age-related juvenile macular degeneration occurs due to the growth of abnormal blood vessels beneath the retina and usually leads to rapid vision loss.
Juvenile Macular Degeneration Market Analysis by Region
The market segmentation by region includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. The United States is a major market for juvenile macular degeneration owing to the significant investment in gene therapy and innovative treatments for the treatment of this eye disorder. The presence of key market players and the high healthcare expenditure also favor market expansion. Additionally, heightened awareness about genetic retinal diseases and the rise in government-funded initiatives are poised to impact the market dynamics in the region.
Leading Players in the Juvenile Macular Degeneration Market
The key features of the market report comprise patent analysis, grants analysis, clinical trial analysis, funding and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:
Pfizer Inc.
Pfizer has a strong focus on the development of biologics and gene therapies for the treatment of retinal diseases. The company is also actively involved in strategic partnerships and acquisitions to boost its gene therapy pipeline.
Bayer AG
Bayer AG, a leading pharmaceutical and biomedical company headquartered in Leverkusen, Germany, is a key market player. The company significantly invests in innovative products and research to meet the needs of people impacted by visual impairment.
F. Hoffmann-La Roche Ltd
Roche has a prominent presence in the market, known for its extensive research in developing therapeutics that cause rapid and severe vision loss. The company is engaged in several clinical trials and developing innovative delivery systems for inherited retinal diseases.
Novartis AG
Swiss multinational pharmaceutical corporation Novartis AG is one of the leading companies in the market, known for its robust efforts to discover interventions that help in protecting and restoring vision. The company is leveraging a patient-centric approach to develop its diverse portfolio of compounds aimed at patients affected by vision loss.
Other key players in the market include Panoptica Pharma, Bausch + Lomb, Regeneron Pharmaceuticals Inc., Ocugen Inc., REGENXBIO Inc., and Oxurion NV.
Key Questions Answered in the Juvenile Macular Degeneration Market Report
Juvenile Macular Degeneration Market Overview
Juvenile macular degeneration or juvenile macular dystrophy refers to a group of inherited eye disorders that occur in children and young adults. This eye condition impacts the central vision and, unlike age-related macular degeneration (AMD), impairs vision early in life. Stargardt disease is the most common form of juvenile macular dystrophy and usually results in a vision of 20/200.
The juvenile macular degeneration market is driven by the increasing prevalence of genetic eye disorders and the rising public awareness about the disease. The advancements in genetic testing and imaging technologies are also benefitting the market by augmenting the number of diagnosed cases. The growth in the volume of clinical trials investigating gene therapies and the increased focus on stem cell treatments are anticipated to bolster the market expansion in the forecast period.
Juvenile Macular Degeneration Market Growth Drivers
Increasing Cases of Juvenile Macular Degeneration to Impact Market Growth
Juvenile macular degeneration (JMD) includes inherited eye disorders such as Stargardt's disease, Best disease, and juvenile retinoschisis, which leads to central vision loss during childhood or young adulthood. In the United States, around 1 in 10,000 children are affected by Stargardt's disease. Further, it is estimated that the disease affects nearly 100,000 individuals in the United States and Europe. The growing awareness of the disease is leading to better diagnosis and management of this inherited eye condition along with prompting the affected individuals to seek treatment. Thus, the increasing cases of genetic eye disorders and the rise in the early detection of juvenile macular degeneration are projected to drive market growth in the coming years.
Juvenile Macular Degeneration Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Regulatory Support to Affect the Market Landscape Significantly
In January 2024, privately held biotech Ascidian Therapeutics announced that the US Food and Drug Administration (FDA) approved its investigational new drug (IND) application and also granted fast-track designation to its RNA-editing candidate (ACDN-01) for the treatment of Stargardt disease, allowing the company to initiate the first RNA-editing clinical trial in the United States. Such regulatory support to advance treatment for inherited eye disorders is likely to stimulate market growth in the forecast period.
Launch of Innovative Products Poised to Augment Juvenile Macular Degeneration Market Demand
In November 2023, Ocutrx Technologies, Inc., a high-tech 3D visualization company specializing in augmented reality (AR) technology, revealed its new AR/XR headset OcuLenz™, which is designed to improve visual clarity for individuals affected by advanced macular degeneration (AMD) and Stargardts (the juvenile form of AMD). The launch of such innovative products to aid people suffering from central vision loss is expected to boost the market demand.
Rising Innovations in Ophthalmology to Elevate the Juvenile Macular Degeneration Market Value
One of the significant market trends is the introduction of advanced imaging technologies, such as adaptive optics and high-resolution OCT, that facilitate detailed visualization and accurate progression of retinal disease. This also helps in evaluating the effectiveness of new therapies and is projected to encourage pharmaceutical companies to invest in the market.
Growth in Clinical Trials to Boost Juvenile Macular Degeneration Market Size
In August 2024, United States-based Ocugen, Inc., a biotech firm that develops novel gene therapies, cell therapies, and vaccines, announced the completion of dosing in the third cohort of its Phase 1/2 GARDian clinical trial that is investigating a modifier gene therapy candidate, OCU410ST (AAV-hRORA), for Stargardt disease. The surge in the number of clinical trials for inherited retinal disorders is poised to augment the market size.
Juvenile Macular Degeneration Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Type:
- Dry Age-related Juvenile Macular Degeneration
- Wet Age-related Juvenile Macular Degeneration
- Early-stage AMD
- Intermediate AMD
- Late-stage AMD
- Drugs
- Anti-vascular Endothelial Growth Factor
- Dietary Supplements
- Others
- Devices
- Glasses
- Contact Lenses
- Others
- Surgery
- Intravenous Route
- Intravitreal Route
- Kids
- Teenagers
- Inherited
- Acquired
- Hospitals & Clinics
- Ambulatory Surgical Centers
- Homecare Settings
- Others
- Hospitals Pharmacies
- Independent Pharmacies
- Online Pharmacies
- Others
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- India
Market Segmentation Based on Type is Anticipated to Witness Substantial Growth Based on the type of juvenile macular degeneration, the market is segmented into dry age-related juvenile macular degeneration and wet age-related juvenile macular degeneration. Dry age-related juvenile macular degeneration is the more common form of juvenile macular degeneration, characterized by the accumulation of drusen (small yellow deposits) beneath the retina and slower progression than the wet form. On the other hand, wet age-related juvenile macular degeneration occurs due to the growth of abnormal blood vessels beneath the retina and usually leads to rapid vision loss.
Juvenile Macular Degeneration Market Analysis by Region
The market segmentation by region includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. The United States is a major market for juvenile macular degeneration owing to the significant investment in gene therapy and innovative treatments for the treatment of this eye disorder. The presence of key market players and the high healthcare expenditure also favor market expansion. Additionally, heightened awareness about genetic retinal diseases and the rise in government-funded initiatives are poised to impact the market dynamics in the region.
Leading Players in the Juvenile Macular Degeneration Market
The key features of the market report comprise patent analysis, grants analysis, clinical trial analysis, funding and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:
Pfizer Inc.
Pfizer has a strong focus on the development of biologics and gene therapies for the treatment of retinal diseases. The company is also actively involved in strategic partnerships and acquisitions to boost its gene therapy pipeline.
Bayer AG
Bayer AG, a leading pharmaceutical and biomedical company headquartered in Leverkusen, Germany, is a key market player. The company significantly invests in innovative products and research to meet the needs of people impacted by visual impairment.
F. Hoffmann-La Roche Ltd
Roche has a prominent presence in the market, known for its extensive research in developing therapeutics that cause rapid and severe vision loss. The company is engaged in several clinical trials and developing innovative delivery systems for inherited retinal diseases.
Novartis AG
Swiss multinational pharmaceutical corporation Novartis AG is one of the leading companies in the market, known for its robust efforts to discover interventions that help in protecting and restoring vision. The company is leveraging a patient-centric approach to develop its diverse portfolio of compounds aimed at patients affected by vision loss.
Other key players in the market include Panoptica Pharma, Bausch + Lomb, Regeneron Pharmaceuticals Inc., Ocugen Inc., REGENXBIO Inc., and Oxurion NV.
Key Questions Answered in the Juvenile Macular Degeneration Market Report
- What was the juvenile macular degeneration market value in 2024?
- What is the juvenile macular degeneration market forecast outlook for 2025-2034?
- What are the regional markets covered in the EMR report?
- What is market segmentation based on type?
- What is the market breakup based on disease stage?
- What is the market breakup by treatment type?
- What is market segmentation based on the route of administration?
- What is market segmentation by age group?
- What is market segmentation based on disease type?
- What are the end users of the market?
- What are the major distribution channels of the market?
- What are the major factors aiding the juvenile macular degeneration market demand?
- How has the market performed so far and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- How do the prevalence and incidence of juvenile macular degeneration affect the market landscape?
- What are the major juvenile macular degeneration market trends?
- How does the growth in clinical trials impact the market size?
- Which type of juvenile macular degeneration will dominate the market share?
- Which disease stage is expected to have a high market value in the coming years?
- Which treatment type will experience the highest demand in the market segment?
- Which route of administration is poised to lead the market share?
- Which age group is likely to have a high market value?
- Which disease type is anticipated to fuel market demand?
- Which end user is projected to contribute to the highest market growth?
- Which distribution channel is poised to lead the market share?
- Who are the key players involved in the juvenile macular degeneration market?
- What is the patent landscape of the market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?
Table of Contents
400 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Juvenile Macular Degeneration Market Overview – 8 Major Markets
- 3.1 Juvenile Macular Degeneration Market Historical Value 2018-2024
- 3.2 Juvenile Macular Degeneration Market Forecast Value 2025-2034
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Juvenile Macular Degeneration Overview
- 5.1 Guidelines and Stages
- 5.2 Pathophysiology
- 5.3 Screening and Diagnosis
- 5.4 Treatment Pathway
- 6 Patient Profile
- 6.1 Patient Profile Overview
- 6.2 Patient Psychology and Emotional Impact Factors
- 6.3 Risk Assessment and Treatment Success Rate
- 7 Juvenile Macular Degeneration Market - Epidemiology Scenario and Forecast – 8 Major Markets
- 7.1 8MM Epidemiology Scenario Overview 2018-2034
- 7.2 Prevalence, by Country
- 7.2.1 United States
- 7.2.2 United Kingdom
- 7.2.3 EU4
- 7.2.4 India
- 7.2.5 Japan
- 7.3 Diagnosed Cases, by Country
- 7.3.1 United States
- 7.3.2 United Kingdom
- 7.3.3 EU4
- 7.3.4 India
- 7.3.5 Japan
- 7.4 Treatment Seeking Rate, by Country
- 7.4.1 United States
- 7.4.2 United Kingdom
- 7.4.3 EU4
- 7.4.4 India
- 7.4.5 Japan
- 8 Juvenile Macular Degeneration Market Landscape – 8 Major Markets
- 8.1 Juvenile Macular Degeneration Market: Developers Landscape
- 8.1.1 Analysis by Year of Establishment
- 8.1.2 Analysis by Company Size
- 8.1.3 Analysis by Region
- 8.2 Juvenile Macular Degeneration Market: Product Landscape
- 8.2.1 Analysis by Type
- 8.2.2 Analysis by Treatment Type
- 8.2.3 Analysis by Route of Administration
- 9 Juvenile Macular Degeneration Market Challenges and Unmet Needs
- 9.1 Treatment Pathway Challenges
- 9.2 Compliance and Drop-Out Analysis
- 9.3 Awareness and Prevention Gaps
- 10 Cost of Treatment
- 11 Juvenile Macular Degeneration Market Dynamics
- 11.1 Market Drivers and Constraints
- 11.2 SWOT Analysis
- 11.2.1 Strengths
- 11.2.2 Weaknesses
- 11.2.3 Opportunities
- 11.2.4 Threats
- 11.3 PESTEL Analysis
- 11.3.1 Political
- 11.3.2 Economic
- 11.3.3 Social
- 11.3.4 Technological
- 11.3.5 Legal
- 11.3.6 Environment
- 11.4 Porter’s Five Forces Model
- 11.4.1 Bargaining Power of Suppliers
- 11.4.2 Bargaining Power of Buyers
- 11.4.3 Threat of New Entrants
- 11.4.4 Threat of Substitutes
- 11.4.5 Degree of Rivalry
- 11.5 Key Demand Indicators
- 11.6 Key Price Indicators
- 11.7 Industry Events, Initiatives, and Trends
- 11.8 Value Chain Analysis
- 12 Juvenile Macular Degeneration Market Segmentation 218-2034 - 8 Major Markets
- 12.1 Juvenile Macular Degeneration Market 2018-2034 by Type
- 12.1.1 Market Overview
- 12.1.2 Dry Age-related Juvenile Macular Degeneration
- 12.1.3 Wet Age-related Juvenile Macular Degeneration
- 12.2 Juvenile Macular Degeneration Market 2018-2034 by Disease Stage
- 12.2.1 Market Overview
- 12.2.2 Early-stage AMD
- 12.2.3 Intermediate AMD
- 12.2.4 Late-stage AMD
- 12.3 Juvenile Macular Degeneration Market 2018-2034 by Treatment Type
- 12.3.1 Market Overview
- 12.3.2 Drugs
- 12.3.2.1 Anti-vascular Endothelial Growth Factor
- 12.3.2.2 Dietary Supplements
- 12.3.2.3 Others
- 12.3.3 Devices
- 12.3.3.1 Glasses
- 12.3.3.2 Contact Lenses
- 12.3.3.3 Others
- 12.3.4 Surgery
- 12.4 Juvenile Macular Degeneration Market 2018-2034 by Route of Administration
- 12.4.1 Market Overview
- 12.4.2 Intravenous Route
- 12.4.3 Intravitreal Route
- 12.5 Juvenile Macular Degeneration Market 2018-2034 by Age Group
- 12.5.1 Market Overview
- 12.5.2 Kids
- 12.5.3 Teenagers
- 12.6 Juvenile Macular Degeneration Market 2018-2034 by Disease Type
- 12.6.1 Market Overview
- 12.6.2 Inherited
- 12.6.3 Acquired
- 12.7 Juvenile Macular Degeneration Market 2018-2034 by End User
- 12.7.1 Market Overview
- 12.7.2 Hospitals & Clinics
- 12.7.3 Ambulatory Surgical Centers
- 12.7.4 Homecare Settings
- 12.7.5 Others
- 12.8 Juvenile Macular Degeneration Market 2018-2034 by Distribution Channel
- 12.8.1 Market Overview
- 12.8.2 Hospitals Pharmacies
- 12.8.3 Independent Pharmacies
- 12.8.4 Online Pharmacies
- 12.8.5 Others
- 12.9 Juvenile Macular Degeneration Market 2018-2034 by Region
- 12.9.1 Market Overview
- 12.9.2 United States
- 12.9.3 EU-4 and the United Kingdom
- 12.9.3.1 Germany
- 12.9.3.2 France
- 12.9.3.3 Italy
- 12.9.3.4 Spain
- 12.9.3.5 United Kingdom
- 12.9.4 Japan
- 12.9.5 India
- 13 United States Juvenile Macular Degeneration Market 218-2034
- 13.1 United States Juvenile Macular Degeneration Market 2018-2034 by Type
- 13.1.1 Market Overview
- 13.1.2 Dry Age-related Juvenile Macular Degeneration
- 13.1.3 Wet Age-related Juvenile Macular Degeneration
- 13.2 United States Juvenile Macular Degeneration Market 2018-2034 by Disease Stage
- 13.2.1 Market Overview
- 13.2.2 Early-stage AMD
- 13.2.3 Intermediate AMD
- 13.2.4 Late-stage AMD
- 13.3 United States Juvenile Macular Degeneration Market 2018-2034 by Treatment Type
- 13.3.1 Market Overview
- 13.3.2 Drugs
- 13.3.2.1 Anti-vascular Endothelial Growth Factor
- 13.3.2.2 Dietary Supplements
- 13.3.2.3 Others
- 13.3.3 Devices
- 13.3.3.1 Glasses
- 13.3.3.2 Contact Lenses
- 13.3.3.3 Others
- 13.3.4 Surgery
- 13.4 United States Juvenile Macular Degeneration Market 2018-2034 by Route of Administration
- 13.4.1 Market Overview
- 13.4.2 Intravenous Route
- 13.4.3 Intravitreal Route
- 13.5 United States Juvenile Macular Degeneration Market 2018-2034 by Age Group
- 13.5.1 Market Overview
- 13.5.2 Kids
- 13.5.3 Teenagers
- 13.6 United States Juvenile Macular Degeneration Market 2018-2034 by Disease Type
- 13.6.1 Market Overview
- 13.6.2 Inherited
- 13.6.3 Acquired
- 13.7 United States Juvenile Macular Degeneration Market 2018-2034 by End User
- 13.7.1 Market Overview
- 13.7.2 Hospitals & Clinics
- 13.7.3 Ambulatory Surgical Centers
- 13.7.4 Homecare Settings
- 13.7.5 Others
- 13.8 United States Juvenile Macular Degeneration Market 2018-2034 by Distribution Channel
- 13.8.1 Market Overview
- 13.8.2 Hospitals Pharmacies
- 13.8.3 Independent Pharmacies
- 13.8.4 Online Pharmacies
- 13.8.5 Others
- 14 EU-4 and United Kingdom Juvenile Macular Degeneration Market 218-2034
- 14.1 EU-4 and United Kingdom Juvenile Macular Degeneration Market 2018-2034 by Type
- 14.1.1 Market Overview
- 14.1.2 Dry Age-related Juvenile Macular Degeneration
- 14.1.3 Wet Age-related Juvenile Macular Degeneration
- 14.2 EU-4 and United Kingdom Juvenile Macular Degeneration Market 2018-2034 by Disease Stage
- 14.2.1 Market Overview
- 14.2.2 Early-stage AMD
- 14.2.3 Intermediate AMD
- 14.2.4 Late-stage AMD
- 14.3 EU-4 and United Kingdom Juvenile Macular Degeneration Market 2018-2034 by Treatment Type
- 14.3.1 Market Overview
- 14.3.2 Drugs
- 14.3.2.1 Anti-vascular Endothelial Growth Factor
- 14.3.2.2 Dietary Supplements
- 14.3.2.3 Others
- 14.3.3 Devices
- 14.3.3.1 Glasses
- 14.3.3.2 Contact Lenses
- 14.3.3.3 Others
- 14.3.4 Surgery
- 14.4 EU-4 and United Kingdom Juvenile Macular Degeneration Market 2018-2034 by Route of Administration
- 14.4.1 Market Overview
- 14.4.2 Intravenous Route
- 14.4.3 Intravitreal Route
- 14.5 EU-4 and United Kingdom Juvenile Macular Degeneration Market 2018-2034 by Age Group
- 14.5.1 Market Overview
- 14.5.2 Kids
- 14.5.3 Teenagers
- 14.6 EU-4 and United Kingdom Juvenile Macular Degeneration Market 2018-2034 by Disease Type
- 14.6.1 Market Overview
- 14.6.2 Inherited
- 14.6.3 Acquired
- 14.7 EU-4 and United Kingdom Juvenile Macular Degeneration Market 2018-2034 by End User
- 14.7.1 Market Overview
- 14.7.2 Hospitals & Clinics
- 14.7.3 Ambulatory Surgical Centers
- 14.7.4 Homecare Settings
- 14.7.5 Others
- 14.8 EU-4 and United Kingdom Juvenile Macular Degeneration Market 2018-2034 by Distribution Channel
- 14.8.1 Market Overview
- 14.8.2 Hospitals Pharmacies
- 14.8.3 Independent Pharmacies
- 14.8.4 Online Pharmacies
- 14.8.5 Others
- 15 Japan Juvenile Macular Degeneration Market 218-2034
- 15.1 Japan Juvenile Macular Degeneration Market 2018-2034 by Type
- 15.1.1 Market Overview
- 15.1.2 Dry Age-related Juvenile Macular Degeneration
- 15.1.3 Wet Age-related Juvenile Macular Degeneration
- 15.2 Japan Juvenile Macular Degeneration Market 2018-2034 by Disease Stage
- 15.2.1 Market Overview
- 15.2.2 Early-stage AMD
- 15.2.3 Intermediate AMD
- 15.2.4 Late-stage AMD
- 15.3 Japan Juvenile Macular Degeneration Market 2018-2034 by Treatment Type
- 15.3.1 Market Overview
- 15.3.2 Drugs
- 15.3.2.1 Anti-vascular Endothelial Growth Factor
- 15.3.2.2 Dietary Supplements
- 15.3.2.3 Others
- 15.3.3 Devices
- 15.3.3.1 Glasses
- 15.3.3.2 Contact Lenses
- 15.3.3.3 Others
- 15.3.4 Surgery
- 15.4 Japan Juvenile Macular Degeneration Market 2018-2034 by Route of Administration
- 15.4.1 Market Overview
- 15.4.2 Intravenous Route
- 15.4.3 Intravitreal Route
- 15.5 Japan Juvenile Macular Degeneration Market 2018-2034 by Age Group
- 15.5.1 Market Overview
- 15.5.2 Kids
- 15.5.3 Teenagers
- 15.6 Japan Juvenile Macular Degeneration Market 2018-2034 by Disease Type
- 15.6.1 Market Overview
- 15.6.2 Inherited
- 15.6.3 Acquired
- 15.7 Japan Juvenile Macular Degeneration Market 2018-2034 by End User
- 15.7.1 Market Overview
- 15.7.2 Hospitals & Clinics
- 15.7.3 Ambulatory Surgical Centers
- 15.7.4 Homecare Settings
- 15.7.5 Others
- 15.8 Japan Juvenile Macular Degeneration Market 2018-2034 by Distribution Channel
- 15.8.1 Market Overview
- 15.8.2 Hospitals Pharmacies
- 15.8.3 Independent Pharmacies
- 15.8.4 Online Pharmacies
- 15.8.5 Others
- 16 India Juvenile Macular Degeneration Market 218-2034
- 16.1 India Juvenile Macular Degeneration Market 2018-2034 by Type
- 16.1.1 Market Overview
- 16.1.2 Dry Age-related Juvenile Macular Degeneration
- 16.1.3 Wet Age-related Juvenile Macular Degeneration
- 16.2 India Juvenile Macular Degeneration Market 2018-2034 by Disease Stage
- 16.2.1 Market Overview
- 16.2.2 Early-stage AMD
- 16.2.3 Intermediate AMD
- 16.2.4 Late-stage AMD
- 16.3 India Juvenile Macular Degeneration Market 2018-2034 by Treatment Type
- 16.3.1 Market Overview
- 16.3.2 Drugs
- 16.3.2.1 Anti-vascular Endothelial Growth Factor
- 16.3.2.2 Dietary Supplements
- 16.3.2.3 Others
- 16.3.3 Devices
- 16.3.3.1 Glasses
- 16.3.3.2 Contact Lenses
- 16.3.3.3 Others
- 16.3.4 Surgery
- 16.4 India Juvenile Macular Degeneration Market 2018-2034 by Route of Administration
- 16.4.1 Market Overview
- 16.4.2 Intravenous Route
- 16.4.3 Intravitreal Route
- 16.5 India Juvenile Macular Degeneration Market 2018-2034 by Age Group
- 16.5.1 Market Overview
- 16.5.2 Kids
- 16.5.3 Teenagers
- 16.6 India Juvenile Macular Degeneration Market 2018-2034 by Disease Type
- 16.6.1 Market Overview
- 16.6.2 Inherited
- 16.6.3 Acquired
- 16.7 India Juvenile Macular Degeneration Market 2018-2034 by End User
- 16.7.1 Market Overview
- 16.7.2 Hospitals & Clinics
- 16.7.3 Ambulatory Surgical Centers
- 16.7.4 Homecare Settings
- 16.7.5 Others
- 16.8 India Juvenile Macular Degeneration Market 2018-2034 by Distribution Channel
- 16.8.1 Market Overview
- 16.8.2 Hospitals Pharmacies
- 16.8.3 Independent Pharmacies
- 16.8.4 Online Pharmacies
- 16.8.5 Others
- 17 Regulatory Framework
- 17.1 Regulatory Overview
- 17.2 US FDA
- 17.3 EU EMA
- 17.4 Japan PMDA
- 17.5 India CDSCO
- 17.6 Others
- 18 Patent Analysis
- 18.1 Analysis by Type of Patent
- 18.2 Analysis by Publication Year
- 18.3 Analysis by Issuing Authority
- 18.4 Analysis by Patent Age
- 18.5 Analysis by CPC Analysis
- 18.6 Analysis by Patent Valuation
- 19 Clinical Trials Analysis
- 19.1 Analysis by Trial Registration Year
- 19.2 Analysis by Trial Status
- 19.3 Analysis by Trial Phase
- 19.4 Analysis by Therapeutic Area
- 19.5 Analysis by Geography
- 20 Grants Analysis
- 20.1 Analysis by Year
- 20.2 Analysis by Amount Awarded
- 20.3 Analysis by Issuing Authority
- 20.4 Analysis by Grant Application
- 20.5 Analysis by Funding Institute
- 20.6 Analysis by NIH Departments
- 20.7 Analysis by Recipient Organization
- 21 Funding and Investment Analysis
- 21.1 Analysis by Funding Instances
- 21.2 Analysis by Drug Class of Funding
- 21.3 Analysis by Funding Amount
- 21.4 Analysis by Leading Players
- 21.5 Analysis by Leading Investors
- 21.6 Analysis by Geography
- 22 Strategic Initiatives
- 22.1 Analysis by Partnership Instances
- 22.2 Analysis by Drug Class of Partnership
- 22.3 Analysis by Leading Players
- 22.4 Analysis by Geography
- 23 Supplier Landscape
- 23.1 Market Share Analysis, By Region (Top 5 Companies)
- 23.2 Pfizer, Inc.
- 23.2.1 Financial Analysis
- 23.2.2 Product Portfolio
- 23.2.3 Demographic Reach and Achievements
- 23.2.4 Companies News and Developments
- 23.2.5 Certifications
- 23.3 Bayer AG
- 23.3.1 Financial Analysis
- 23.3.2 Product Portfolio
- 23.3.3 Demographic Reach and Achievements
- 23.3.4 Companies News and Developments
- 23.3.5 Certifications
- 23.4 F-Hoffmann La Roche Ltd.
- 23.4.1 Financial Analysis
- 23.4.2 Product Portfolio
- 23.4.3 Demographic Reach and Achievements
- 23.4.4 Companies News and Developments
- 23.4.5 Certifications
- 23.5 Novartis AG
- 23.5.1 Financial Analysis
- 23.5.2 Product Portfolio
- 23.5.3 Demographic Reach and Achievements
- 23.5.4 Companies News and Developments
- 23.5.5 Certifications
- 23.6 Panoptica Pharma
- 23.6.1 Financial Analysis
- 23.6.2 Product Portfolio
- 23.6.3 Demographic Reach and Achievements
- 23.6.4 Companies News and Developments
- 23.6.5 Certifications
- 23.7 Bausch + Lomb
- 23.7.1 Financial Analysis
- 23.7.2 Product Portfolio
- 23.7.3 Demographic Reach and Achievements
- 23.7.4 Companies News and Developments
- 23.7.5 Certifications
- 23.8 Regeneron Pharmaceuticals Inc.
- 23.8.1 Financial Analysis
- 23.8.2 Product Portfolio
- 23.8.3 Demographic Reach and Achievements
- 23.8.4 Companies News and Developments
- 23.8.5 Certifications
- 23.9 Ocugen Inc.
- 23.9.1 Financial Analysis
- 23.9.2 Product Portfolio
- 23.9.3 Demographic Reach and Achievements
- 23.9.4 Companies News and Developments
- 23.9.5 Certifications
- 23.10 Oxurion NV
- 23.10.1 Financial Analysis
- 23.10.2 Product Portfolio
- 23.10.3 Demographic Reach and Achievements
- 23.10.4 Companies News and Developments
- 23.10.5 Certifications
- 23.11 REGENXBIO Inc.
- 23.11.1 Financial Analysis
- 23.11.2 Product Portfolio
- 23.11.3 Demographic Reach and Achievements
- 23.11.4 Companies News and Developments
- 23.11.5 Certifications
- 24 Juvenile Macular Degeneration Market - Distribution Model (Additional Insight)
- 24.1 Overview
- 24.2 Potential Distributors
- 24.3 Key Parameters for Distribution Partner Assessment
- 25 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 26 Payment Methods (Additional Insight)
- 26.1 Government Funded
- 26.2 Private Insurance
- 26.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
